Study Coordinator in the following clinical trials:

• Efficacy and safety assessment of T4030 eye drops versus Ganfort® UD in ocular hypertensive or glaucomatous patients (LT4030-301).

• A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension (TRITON 1698-301-007).

• Basic human research study of novel glaucoma endpoints and identification of optimal patient populations for neuroprotection trials (CBASICHR0031).

• Evaluation of spatial summation in the central 10 degrees of the visual field: development of a neural model for structure-function analysis.

• Phase III, multinational, multicenter, investigator-masked, randomized, active-controlled study to compare the efficacy and safety of DE-130A versus Xalatan® in patients with open-angle glaucoma or ocular hypertension over 3 months, followed by a 12-month open-label follow-up with DE-130A treatment (CATIOPROST – 0130A01SA).

Sub-Investigator in the following clinical trials:

• Modulation of neuronal connectivity along the visual pathways in glaucoma patients through oral citicoline solution treatment: a multimodal morpho-functional study.

• 24-hour efficacy and tolerability of the preservative-free fixed-dose tafluprost-timolol combination in glaucomatous or ocular hypertensive patients previously treated with BAK-preserved latanoprost. A 3-month prospective, open-label study (HERO).

• Evaluation of agreement in the diagnosis of glaucoma progression by visual field testing.

• Using crowd-sourced assessment by glaucoma specialists to establish a glaucoma definition for clinical research (CSGS).

• Evaluation of the efficacy and safety of T4032 (bimatoprost 0.1% preservative-free) versus Lumigan 0.01% in patients with ocular hypertension or glaucoma (LT4032-301).

• Measurement of test-retest variability in glaucoma patients using Compass fundus perimeter (CMP-003).

• Evaluation of the effect on visual function of liposomal citicoline eye drops as an adjunct to IOP-lowering therapy in glaucoma patients (OMK1_LF).

• Evaluation of vitreous citicoline concentration after topical ocular administration: ocular pharmacokinetics study in humans (OMK12017).

• A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and IOP-lowering efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03%/timolol 0.5%) in subjects with elevated IOP (MERCURY 3).

• Preservative-free fixed-dose combination of tafluprost 0.0015% / timolol 0.5% in open-angle glaucoma or ocular hypertension: clinical effectiveness, tolerability, and safety in a real-world setting.

• Efficacy of a taurine and hyaluronic acid ophthalmic solution in glaucoma and ocular hypertension patients under chronic IOP-lowering treatment.

• Safety and efficacy of twice-daily brinzolamide 1%/brimonidine 0.2% (SIMBRINZA) as adjunctive therapy to travoprost 0.004%/timolol 0.5% (DUOTRAV).

• Intraocular pressure and tolerability study of preserved bimatoprost 0.1% (BMD) or preservative-free tafluprost (Saflutan®) in ocular hypertension or glaucoma patients: randomized, single-masked, 3-month, crossover, European multicenter trial (SPORT II).

• Clinical performance of Compass in the diagnosis of glaucoma.

• A phase IV study on ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort® to Taptiquom® eye drops.

• Evaluation of plasma and tear levels of BDNF and NGF in glaucoma patients (NTs and glaucoma).

• Side effects of preservatives: clinical, cytological, and instrumental evaluation of the ocular surface.

• Intraocular pressure and tolerability study of preservative-free bimatoprost 0.03% (BUDPF) or preservative-free latanoprost 0.005% (LUDPF, Monoprost®) in ocular hypertension or glaucoma patients: randomized, single-masked, 3-month crossover, European multicenter trial (SPORT).

• Comparison between bimatoprost-timolol fixed-dose combination and carbonic anhydrase inhibitor-timolol combinations in patients with glaucoma or ocular hypertension uncontrolled by monotherapy: retrospective study.

• Efficacy of a cobalamin, taurine, and hyaluronic acid ophthalmic solution in patients under IOP-lowering therapy.

• Evaluation of the IOP-lowering efficacy of Miotrab administered three times daily.

• Lumigan® 0.1% in daily clinical practice: retrospective study.

• Learning effect of Heidelberg Edge Perimeter (HEP) perimetry in ocular hypertension patients.

• Effect of pupil dilation on RNFL, ONH, and GCC measurements with spectral-domain OCT (RTVue-100).

• Prospective longitudinal study of ocular surface disease development in treatment-naïve ocular hypertension/glaucoma patients compared to healthy controls (SAHARA).

• Therapeutic equivalence evaluation of Travoprost PR and Travatan®: randomized, double-masked study in glaucoma or ocular hypertension patients.

• Two-year, multicenter, double-masked, parallel-group study assessing the safety of LUMIGAN® 0.1 mg/ml versus LUMIGAN® 0.3 mg/ml in glaucoma or ocular hypertension patients.

• Phase III, randomized, double-masked, 6-month study comparing the preservative-free tafluprost 0.0015%/timolol 0.5% fixed-dose combination with individual monotherapies in open-angle glaucoma or ocular hypertension patients.

• Comparison of circadian IOP-lowering effects of bimatoprost 0.01% versus timolol 0.5%.

• Multicenter study on efficacy and tolerability of travoprost 0.004% with Polyquad® preservative in patients previously on latanoprost 0.005% or bimatoprost 0.01% monotherapy.

• Evaluation of glaucomatous patients with RNFL abnormalities using SITA Standard and SITA SWAP perimetry.

• Comparison between the Moorfields MDT and established perimeters to discriminate between normal and glaucomatous eyes.